{"product_id":"resmed-pestle-analysis","title":"ResMed PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic trends, and emerging technologies are reshaping ResMed’s market position with our concise PESTLE snapshot—designed for investors and strategists who need fast, actionable insight; purchase the full analysis to access the complete, editable report and make smarter decisions instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Trade and Tariff Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed's global supply chain spans manufacturing in Australia, Singapore and the US, exposing it to tariff risk as global trade tensions rise; in 2024 ResMed reported 2023 revenue of $4.9B, so even modest tariff increases (eg 5%) on imported components could materially raise COGS. Strategists must track US-China and EU trade frictions and consider relocating production to lower-tariff jurisdictions to avoid margin erosion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Spending Levels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic health budgets shape access to sleep apnea and COPD treatments via national reimbursement; in 2024 EU health spending averaged 9.8% of GDP and many countries reimburse CPAP\/BiPAP devices, directly affecting ResMed's prescriptions and uptake.\u003c\/p\u003e\n\u003cp\u003ePolitical shifts alter subsidized healthcare priorities—since 2020, policy changes in parts of Europe and Asia have led to reimbursement reviews affecting device coverage, influencing ResMed's market penetration.\u003c\/p\u003e\n\u003cp\u003eResMed depends on stable government funding for device volumes; in FY2025 management noted over 40% of revenue tied to reimbursed markets, making funding volatility a material risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Approval Processes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical stability in bodies like the FDA and EMA directly affects ResMed's launch timelines; FDA 510(k) median review time rose to 247 days in 2024 vs 227 days in 2021, slowing product rollouts. Administrative backlogs and shifting mandates—eg increased post-market surveillance requirements introduced in EU MDR updates—can delay certification of new ventilators and CPAPs, compressing ResMed's innovation-to-revenue window. Navigating these regimes is critical to preserve market share and the company’s FY2025 R\u0026amp;D-driven growth targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Stability in Key Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegional conflicts and political unrest can disrupt ResMed’s distribution and local sales in emerging markets; for example, 2024 supply-chain delays in Eastern Europe raised logistics costs by an estimated 3–5%, impacting Q3 regional revenue trends.\u003c\/p\u003e\n\u003cp\u003eResMed’s expansion into Eastern Europe and parts of Asia remains sensitive to infrastructure and customs volatility—these markets represented about 12% of FY2024 revenue, increasing exposure to local political risk.\u003c\/p\u003e\n\u003cp\u003eDiversified market exposure across North America, APAC and EMEA helps buffer localized shocks; geographic revenue mix (FY2024: North America ~56%, EMEA ~20%, APAC ~24%) reduces single-region dependency.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 logistics cost increase in Eastern Europe ~3–5%\u003c\/li\u003e\n\u003cli\u003eEastern Europe + Asia account for ~12% of FY2024 revenue\u003c\/li\u003e\n\u003cli\u003eFY2024 geographic mix: NA 56%, EMEA 20%, APAC 24%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Policy Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment-led campaigns elevating sleep and respiratory health—e.g., CDC reports linking untreated sleep apnea to $150 billion annual U.S. health\/safety costs—boost demand for ResMed devices and cloud-based diagnostics.\u003c\/p\u003e\n\u003cp\u003eMandates for screening commercial drivers and high-risk workers expand TAM; EU\/UK and several U.S. states increased occupational screening guidelines between 2022–2025, adding tens of thousands of screened patients annually.\u003c\/p\u003e\n\u003cp\u003eSustained advocacy and lobbying keep sleep health on national agendas; ResMed and industry groups increased policy engagement spending to support reimbursement and screening mandates in 2023–2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCDC cost estimate: $150B U.S. annual burden\u003c\/li\u003e\n\u003cli\u003eOccupational screening uptick 2022–2025: tens of thousands screened\/year\u003c\/li\u003e\n\u003cli\u003eIncreased industry policy spending 2023–2024 to protect reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed: $4.9B revenue, tariff \u0026amp; reimbursement risks amid long FDA review times\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed faces tariff and reimbursement risks: FY2023 revenue $4.9B; FY2024 geographic mix NA 56%, EMEA 20%, APAC 24%; ~40% FY2025 revenue from reimbursed markets. FDA median 510(k) review 247 days (2024). Eastern Europe\/Asia ~12% revenue; 2024 logistics costs there rose ~3–5%. CDC links untreated sleep apnea to $150B US annual burden.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2023 Revenue\u003c\/td\u003e\n\u003ctd\u003e$4.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic mix FY2024\u003c\/td\u003e\n\u003ctd\u003eNA56%\/EMEA20%\/APAC24%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursed markets\u003c\/td\u003e\n\u003ctd\u003e~40% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA 510(k) 2024\u003c\/td\u003e\n\u003ctd\u003e247 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect ResMed across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven subpoints and region-specific trends.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise PESTLE summary of ResMed that highlights key external risks and opportunities for quick inclusion in presentations or strategic meetings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement Rate Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReimbursement rates from Medicare and private insurers directly impact ResMed’s profitability; Medicare payment cuts proposed in 2024 aimed at sleep therapy supplies risk reducing revenue for ResMed and its ~20,000 HME partners. A 5-10% reimbursement decline could compress gross margins below the 50% reported in FY2024. Continuous monitoring of pricing and payor contracts is essential to adapt sales mix and protect operating margin targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of GLP-1 Medications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe rapid adoption of GLP-1 weight-loss drugs (global weekly prescriptions up ~35% in 2024) could lower OSA severity for a subset of patients, potentially trimming future device demand; ResMed positions this as a co-management opportunity, integrating digital monitoring and telehealth to retain care pathways. Analysts should track patient pipeline trends and payor coverage shifts—ResMed reported FY2025 Q1 revenue growth of 12% as it expands software-enabled services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a US-dollar reporter with ~44% of FY2025 revenue generated outside the US—notably EUR, AUD and JPY—ResMed faces material FX risk; a 10% USD strengthening trimmed comparable revenue growth by roughly 3–4% in FY2024. USD appreciation produces adverse translation effects on reported net income and EPS, as seen when USD rose ~8% vs EUR in 2022–23. ResMed employs hedging (forwards\/options) and localized pricing to mitigate volatility and protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and Supply Chain Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising costs for raw materials, semiconductors and global logistics lifted ResMed’s input costs in 2024, contributing to a 4–6% gross margin compression in parts of its mask and device segments versus 2022 levels.\u003c\/p\u003e\n\u003cp\u003eResMed’s efficiency programs and 2024 operating margin of ~22% helped absorb shocks, but persistent inflation risks forcing price hikes that could dampen volume in price-sensitive markets like Latin America and parts of APAC.\u003c\/p\u003e\n\u003cp\u003eRobust inventory turns, strategic supplier consolidation and hedging of key electronic components remain critical to protect margins and preserve global market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 gross margin pressure ~4–6%\u003c\/li\u003e\n\u003cli\u003e2024 operating margin ~22%\u003c\/li\u003e\n\u003cli\u003eKey mitigation: inventory turns, supplier consolidation, component hedging\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Discretionary Income Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWhile core ResMed devices address essential sleep and respiratory needs, out-of-pocket spending on premium masks and accessories is sensitive to economic downturns; US consumer spending on health products fell 2.3% in 2023, indicating potential pressure on elective upgrades.\u003c\/p\u003e\n\u003cp\u003ePeriods of low consumer confidence—US consumer confidence index averaged 103 in 2024 vs 120 in 2021—risk delays in premium software subscription uptake and equipment replacement cycles.\u003c\/p\u003e\n\u003cp\u003eContinued GDP growth in emerging markets (IMF 2024: India 6.6%, Southeast Asia ~4.5%) remains a key driver for expanding ResMed’s global user base and revenue diversification.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOut-of-pocket sensitivity: higher-priced accessories vulnerable in downturns\u003c\/li\u003e\n\u003cli\u003eConsumer confidence drop may delay upgrades\/subscriptions\u003c\/li\u003e\n\u003cli\u003eEmerging market GDP growth (India 6.6% 2024) supports user base expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare cuts, FX \u0026amp; GLP‑1 risks pressure margins despite 12% Q1 revenue growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eReimbursement cuts (Medicare 2024 proposals) risk 5–10% revenue pressure; FY2024 gross margin ~50%, FY2024–24 margin headwind ~4–6%. FY2025 Q1 revenue +12%; operating margin ~22%. USD strength (~10% swing → −3–4% rev impact) and GLP‑1 uptake (~+35% prescriptions 2024) pose demand risk; emerging markets (India GDP 6.6% 2024) support growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 gross margin\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 margin headwind\u003c\/td\u003e\n\u003ctd\u003e4–6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 Q1 rev growth\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin 2024\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD 10% strength impact\u003c\/td\u003e\n\u003ctd\u003e−3–4% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eResMed PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact ResMed PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic planning and investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751427617145,"sku":"resmed-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/resmed-pestle-analysis.png?v=1772231247","url":"https:\/\/growthsharematrix.com\/products\/resmed-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}